Introduction
Growth factors and cytokines regulate a multitude of biological activities that are essential for the development, maintenance and growth of complex organisms. Such events are coordinated through the interaction of these ligands with their corresponding cellular receptors. Ligand-receptor interactions then trigger various signaling transduction pathways, leading to the activation of transcription factors and subsequent changes in the expression of batteries of genes associated with the implementation of an appropriate cellular response. Deregulation of receptor tyrosine kinase (RTK) signaling pathways is a common aberration of transformed cells (Aaronson, 1991) . Hepatocyte growth factor/ scatter factor (HGF/SF) is a pleiotrophic cytokine/ growth factor, able to induce a remarkable variety of biological activities, including cellular proliferation, scattering, tubulogenesis and invasiveness (Gherardi and Stoker, 1991; Rubin et al., 1993; Matsumoto and Nakamura, 1996; Jeers et al., 1996; Weimar et al., 1998) . HGF/SF induces eects through the RTK c-Met, and its signaling constitutes one of the most complex networks currently attributable to an RTK. Upon HGF/SF binding c-Met becomes tyrosine-phosphorylated and engages SH2-containing proteins such as PI3K, phospholipase C-g (PLC-g), Stat3, Src, Grb2 and Gab1. These coupling proteins can activate dierent downstream pathways including the Ras-mitogenic activated protein kinase (MAPK or Erk 1/2) pathway (Weidner et al., 1995; Ponzetto et al., 1996; Weidner et al., 1996) , the PI3K-SAPK/JNK pathway (Rodrigues et al., 1997) and the focal adhesion kinase (FAK) pathway (Chen et al., 1998; Beviglia and Kramer, 1999) . These pathways in turn orchestrate complex HGF/SF functions during embryogenesis and in tumorigenesis, including angiogenesis, degradation of local extracellular matrix, migration and colonization at a distant site (Zarnegar and Michalopoulos, 1995; Matsumoto and Nakamura, 1996; Rosen et al., 1997) . It has been demonstrated that HGF/SF expression is enhanced in some tumors, such as biologically aggressive breast cancers, hepatoblastomas and malignant pleural mesotheliomas (Yamashita et al., 1994; Yao et al., 1996; Tolnay et al., 1998; Weimar et al., 1998; Awasthi and King, 2000) . Chronic activation of c-Met is associated with the development and progression of numerous human and murine tumors, including melanoma (Natali et al., 1993; Ferracini et al., 1995 Ferracini et al., , 1996 Jeers et al., 1996; Otshuka et al., 1998) , and activating c-Met mutations have been reported in patients with papillary renal carcinomas and other cancers (Jeers et al., 1997; Schmidt et al., 1997 Zhuang et al., 1998 Park et al., 1999) .
Mitogenic eects of HGF/SF might be explained, at least partially, by ligand-induced up-regulation of cyclin D1. Cyclin D1 is a regulatory subunit of the CDK holoenzymes that control the activation of pRB (Sherr, 1994; Hunter and Pines, 1994) . Cyclin D1 has been found to collaborate with oncogenes in cellular transformation (Wang et al., 1994) and the protein levels are frequently elevated in uveal-melanomas (Coupland et al., 2000) and primary melanomas that express the tumor suppressor p16
INK4a (Bales et al., 1999) . Cyclin D1 promoter activity and mRNA levels are induced by various growth factors, including epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), platelet-derived growth factor (PDGF), integrin-linked kinase (ILK) and HGF/SF (Musgrove et al., 1993; Filmus et al., 1994; Albanese et al., 1995; Allen et al., 1995; Alberch et al., 1995; Shambaugh et al., 1996; Bennett and Tonks, 1997; D'Amico et al., 2000) . However, the mechanisms by which HGF/SF up-regulates cyclin D1 in melanoma cells have not been fully elucidated. One of the factors implicated in the regulation of cyclin D1 promoter activity is ATF-2 (Albanese et al., 1995; Shambaugh et al., 1996; D'Amico et al., 2000) . The transcription factor ATF-2 controls gene expression via CRE/ATF-2 binding motifs either as a homodimer or heterodimer (Landshultz et al., 1988; Maekawa et al., 1989; Hai et al., 1989) . ATF-2 has never been directly implicated in oncogenesis; however, it enhances resistance to UV irradiation-induced apoptosis of late stage melanoma cells (Ronai et al., 1998) , and cooperates with v-Jun in promoting proliferation and tumor formation (Huguier et al., 1998) . ATF-2 is activated both by JNK/SAPK and p38 stress kinases, and is involved in the transcriptional regulation of a number of oncogenes (i.e. Jun) and cell cycle genes (i.e. cyclin D1) (Kim et al., 1992; van Dam et al., 1993; Tsai et al., 1996; Read et al., 1997; Shimizu et al., 1998) .
Recently, p38 kinase has been implicated in the cytotoxicity of chemical carcinogens Chuang et al., 2000) , scattering (Spector et al., 2000) and metastasis (Taguchi et al., 2000; Huang et al., 2000) . The p38 kinase becomes activated by MKK3/6 and probably other kinases via PI3K (Raingeaud et al., 1996; Macfarlane et al., 1997) . The participation of p38 kinase in the up-regulation of a number of genes involved in cancer and tumor progression, including COX-2, uPAR and cyclin D1 (Saha et al., 1999; Huang et al., 2000) , occurs through the activation of transcription factors such as AP-1, CREB and ATF-2 Ding et al., 1999) .
The diverse array of biological activities ascribed to HGF/SF in dierent cell types suggest the existence of a complex c-Met signaling network, in which interactions between a variety of pathways determine how a given cell will choose to respond to this common stimulus. However, very little is known about c-Met signaling pathways downstream of those factors interacting directly with the receptor. In the present study we demonstrate that HGF/SF stimulates cyclin D1 expression and subsequent proliferation of melanoma cells through the ATF-2 transcription factor. Moreover, p38 kinase and SAPK/JNK activate ATF-2.
Results

HGF/SF up-regulates cyclin D1 in murine melanoma cells
The 37-32 and 37-3N cell lines were established from melanomas arising in HGF/SF transgenic mice. Both melanoma cell lines were found to have appreciable levels of c-Met, and both showed c-Met phosphorylation, 4.8-and 2.8-fold respectively, 5 min after treatment with HGF/SF (40 ng/ml) in serum free medium ( Figure 1a ). HGF/SF can regulate cyclin D1 expression in hepatocytes, muscle satellite cells and melanocytes (Musgrove et al., 1993; Filmus et al., 1994; Albanese et al., 1995; Allen et al., 1995; Alberch et al., 1995; Shambaugh et al., 1996; Bennett and Tonks et , 2000; Halaban, 2000) . We found that cyclin D1 protein was up-regulated by 1.9-and 1.7-fold in 37-3N and 37-32 melanoma cell lines, respectively, 24 h after treatment with HGF/SF ( Figure  1b ). This increase in cyclin D1 protein correlated with the observed activation of c-Met following HGF/SF treatment.
HGF/SF activates transcription factor ATF-2 and p38 kinase
The cyclin D1 promoter contains a CRE/ATF-2 binding site, which has been demonstrated previously to participate in the regulation of cyclin D1 expression (Landshultz et al., 1988; Maekawa et al., 1989; Hai et al., 1989) . We found that upon HGF/SF treatment ATF-2 and CREB become phosphorylated in a timedependent fashion in 37-32 melanoma cells. Western blot analysis using 37-32 nuclear extracts and antiphospho-ATF-2 and anti-phospho-CRE antibodies showed that the maximum activation occurred 30 min after treatment, decaying to near basal levels in a 2-h period ( Figure 2a ). Since both p38 kinase and SAPK/ JNK can activate ATF-2, we transiently transfected 37-32 melanoma cells with either HA-p38 or HA-JNK1 kinase. Kinase reactions using GST-ATF-2 as a substrate showed that both kinases became activated upon HGF/SF stimuli, although p38 phosphorylation of GST-ATF-2 was stronger than SAPK/JNK ( Figure  2b ). Panel 2c shows the time course activation of p38 in 37-32 cells after HGF/SF stimulation. p38 and ATF-2 become activated via the PI3K pathway SAPK/JNK becomes activated upon HGF/SF stimulation via the PI3K pathway (Rodrigues et al., 1997) . However, it is not known which pathway or pathways are implicated in p38-ATF-2 activation by HGF/SF. To begin to address this question, 37-32 cells were transiently transfected with HA-p38 and HA-JNK1, then treated with HGF/SF (40 ng/ml) in the presence or absence of either the p38 kinase-speci®c inhibitor SB203580 or the PI3K-speci®c inhibitor LY294002. A kinase reaction using as a substrate GST-ATF-2 was performed. Figure 3a shows that both the p38 kinase inhibitor SB203580 and the PI3K inhibitor LY294002 inhibited p38 kinase activation by HGF/SF, while SAPK/JNK activation was only inhibited by the PI3K inhibitor. To investigate whether p38 can activate ATF-2 in vivo we treated the cells with HGF/SF in the presence or absence of either the p38 or PI3K inhibitors. Both SB203580 and LY294002 blocked HGF/SF activation of ATF-2 in 37-32 and 37-3N melanoma cells, suggesting that p38 kinase and PI3K are both involved in ATF-2 activation in vivo ( Figure  3b,c) . Although p38 becomes phosphorylated mainly by MKK3/6, we found that MKK3/6 was not activated by HGF/SF; moreover, ATF-2 phosphorylation upon HGF/SF stimulation was not abolished by the over-expression of a transiently transfected MKK6 dominant negative mutant (data not show). In contrast, a transiently transfected dominant negative mutant of p38 partially abolished HGF/SF stimulation of ATF-2 (Figure 3d ). Since ATF-2 is phosphorylated by SAPK/JNK in vitro, we used the SAPK/JNK inhibitor JIP-1 to test whether SAPK/JNK regulates ATF-2 phosphorylation in vivo. The 37-32 cells were transiently transfected with increasing amounts of the SAPK/JNK inhibitor JIP-1. After 24 h transfected cells were treated with 40 ng/ml of HGF/SF for 30 min and ATF-2 phosphorylation was detected by Western blot analysis using an anti-phospho-ATF-2 antibody. Figure 3e shows that JIP-1 was able to inhibit HGF/ SF phosphorylation of ATF-2 when either 1 mg or 5 mg of plasmid was transfected. HGF/SF phosphorylation of ATF-2 was slightly stronger when 0.5 mg of JIP-1 plasmid was transfected.
HGF/SF partially regulates cyclin D1 mRNA expression through p38 and ATF-2 in mouse melanoma cells ATF-2 and CREB regulate the cyclin D1 promoter through ATF-2/CRE binding sites. Since our results indicate that p38 kinase plays a role in ATF-2 activation, we investigated the possible activation of cyclin D1 by Ten mg of protein from nuclear extracts were separated by SDS ± PAGE. The membrane was probed against anti-phospho-ATF-2 antibody. (b) Cells were transfected with 1 mg pCEFL-HA-JNK1 and 1 mg pCEFL-HA-p38. Cells were then treated with HGF/SF for 30 min. HA-JNK1 and HA-p38 were immunoprecipitated using an anti-HA antibody, and a kinase reaction was performed using GST-ATF-2 as a substrate. Kinase reactions were separated by SDS ± PAGE. The same blot was stripped and probed against the anti-HA antibody. (c) Time course of p38 activation upon HGF/SF stimulation in 37-32 cells HGF/SF through p38 kinase. We examined cyclin D1 mRNA induction by HGF/SF during a 48 h-time course. Maximum up-regulation was found 6 h after cells were triggered, and addition of the p38 kinasespeci®c inhibitor SB203580 reduced the mRNA cyclin D1 induction by HGF/SF from 3.17 ± 2.17-fold, showing a partial interference in transcriptional up-regulation (Figure 4a ). These data suggest the participation of p38 kinase in HGF/SF-mediated transcriptional induction of cyclin D1 and a possible role for ATF-2. To test this directly, we co-transfected 37-32 melanoma cells with the 766 cyclin D1 promoter containing the ATF-2/CRE binding site, and with either the dominant negative mutant of p38 kinase or the ATF-2 dominant negative mutant. HGF/SF up-regulated 766 cyclin D1 promoter activity (2.9-fold), which was almost totally blocked by either the dominant negative mutant of p38 kinase (1.5-fold), or the ATF-2 dominant negative mutant (1.2-fold) (Figure 4b ). Figure 4c shows that transient transfection of 37-32 melanoma cells with either the dominant negative mutant of p38, the ATF-2 dominant negative mutant, or the SAPK/JNK inhibitor JIP-1 downregulated cyclin D1 induction by HGF/SF.
HGF/SF activation of p38 kinase promotes proliferation but not motility Two assays were performed to investigate the relative roles of ATF-2 and p38 kinase in 37-32-cell motility and proliferation. A motility assay showed that while speci®c inhibitors for MEK1/2 (PD98059) and P13K (wortmanin) blocked almost completely HGF/SF-promoted motility, the speci®c inhibitor for p38 kinase (SB203580) had no eect on this cellular response (Figure 5a ). In contrast, SB203580 was able to partially block proliferation induced by HGF/SF in 37-32 cells (Figure 5b ).
Discussion
HGF/SF is a pleiotropic cytokine/growth factor, capable of inducing in c-Met expressing cells both Figure 3 p38 and ATF-2 become activated via PI3K. (a) 37-32 melanoma cells were transfected with pCEFL-HA-JNK1 and pCEFL-HA-p38. After 24 h transfected cells were treated for 30 min with HGF/SF (40 ng/ml) in the presence or absence of the p38-or PI3K-speci®c inhibitors, SB2035809 (10 mM) and LY294002 (1.5 mM), respectively. Then HA-JNK1 and HA-p38 proteins were immunoprecipitated and a kinase reaction was performed using GST-ATF-2 as a substrate. Products were separated by SDS ± PAGE and anti-HA was used as a loading control for the kinase reaction. (b) Western blot analysis of 37-32 nuclear extracts, obtained from HGF/SF-induced cells treated with the inhibitor SB2035809 (10 mM) or LY294002 (1.5 mM). Ten mg of protein were separated by SDS ± PAGE and the membrane was probed using an anti-phospho-ATF-2 antibody. (c) pCEFL-HA-p38 was transiently transfected into 37-3N melanoma cells, and a kinase reaction was performed as described in (a). (d) Cells were transfected with either 2 mg of a pCEFL-p38 dominant negative mutant or 2 mg of the pCEFL empty vector. Then p-ATF-2 was detected in nuclear extracts using an anti-phospho-ATF-2 antibody. (e) 37-32 cells were transfected with increasing amounts of JIP-1 and treated with HGF/SF (40 ng/ml), then ATF-2 activation was measured as above. Numbers in (b), (d) 
and (e) indicate fold induction
Oncogene HGF/SF activates melanoma through p38, ATF-2 and cyclin D1 JA Recio and G Merlino The viable number of cells was quanti®ed using the tetrazolium salt WST-1. Cells were treated with 40 ng/ml HGF/SF plus either the MAPK inhibitor SB203508 or PD0980059, and harvested at the times indicated. Bars indicate standard deviation proliferation and motility (Gherardi and Stoker, 1991; Rubin et al., 1993; Jeers et al., 1996; Matsumoto and Nakamura, 1996) , two processes dependent on the complex activation of various pathways involving multiple kinases including Erk 1/2, P13K and SAPK/ JNK (Weidner et al., 1995 (Weidner et al., , 1996 Ponzetto et al., 1996; Rodrigues et al., 1997; Chen et al., 1998; Beviglia and Kramer, 1999) . The signaling pathways regulating ATF-2 function in HGF/SF-treated melanocytic cells have not been elucidated. Here we describe HGF/SF activation of the ATF-2 transcription factor in 37-32 mouse melanoma cells, and the implication of p38 kinase in the regulation of proliferation, but not motility. In contrast to previous studies in which p38 acted as an inhibitor of cyclin D1 in hepatocytes (Awad et al., 2000) , in melanoma cells we found that HGF/SF-mediated induction of proliferation was partially blocked by the speci®c p38-kinase inhibitor SB203580, relative to the complete inhibition observed with the MEK1-speci®c inhibitor PD098059. Although p38 kinase is partially activated through P13K, and P13K has been implicated in HGF/SF-promoted motility (Nakanishi et al., 1999; Lai et al., 2000) , we did not observe any eect on motility by the speci®c p38 kinase inhibitor SB203580. However, we did observe a reduction in motility using either the P13K-speci®c inhibitor wortmanin or the MEK1-speci®c inhibitor PD098059. These data indicate the speci®c participation of p38 kinase in HGF/SFstimulated proliferation, but not motility, raising the possibility that a novel pathway exists between c-Met and p38 kinase in melanoma cells.
The 37-32 melanoma cells were established from HGF/SF transgenic mice and their response to c-Met activation has been demonstrated in earlier studies (Otshuka et al., 1998) . Upon HGF/SF binding to cMet, cyclin D1 RNA transcripts were up-regulated, leading to a proliferative response. Previous studies have demonstrated that the cyclin D1 promoter is regulated by ATF-2 through binding to ATF-2/CRE motifs (Landshultz et al., 1988; Maekawa et al., 1989; Hai et al., 1989) , and that the full induction of cyclin D1 by pp60 -v-src requires the MEK1/ERK, MKK3/p38 and SAPK/JNK pathways in MCF-7 mammary epithelial cell (Ding et al., 1999) . We observed that ATF-2 and CREB became activated in melanoma cells upon HGF/SF binding in a time-dependent fashion. Since p38 kinase and SAPK/JNK are the classic kinases for ATF-2, we assessed the activation of p38 kinase and SAPK/JNK by HGF/SF. Although HGF/ SF activation of SAPK/JNK via P13K has been extensively described (Rodrigues et al., 1997) , HGF/ SF-mediated activation of p38 kinase has been reported only in H441 cells (Awasthi and King, 2000) . Here, we show that HGF/SF activates cyclin D1 and promotes proliferation, at least in part, through the activation of p38 kinase. Activation of p38 by HGF/SF peaked at 15 min, which was consistent with the maximum downstream activation of ATF-2 and CREB at 30 min. The phosphorylation of p38 kinase was partially blocked by the inhibitor LY294002, suggesting that full p38 activation was dependent on the P13K pathway. However, the same PIK-speci®c inhibitor did not totally block HGF/SF activation of ATF-2, indicating that p38 kinase may be stimulated by other pathways as well. Since HGF/SF did not activate MKK3/6, and the over-expression of MKK6 dominant negative did not aect HGF/SF activation of ATF-2, such pathways were not MKK6 dependent. In fact, HGF/SF has been reported to activate other kinases capable of phosphorylating p38 kinase in a P13K-indpendent manner, such as cdc42 (Royal et al., 2000) .
In addition to p38 kinase, we report here that SAPK/JNK can activate ATF-2. Other investigators have demonstrated the activation of SAPK/JNK by growth factors (i.e., VEGF) and G-protein-coupled receptors (i.e., Mas oncogene), and its participation in cell proliferation (Pedram et al., 1998; Zohn et al., 1998) . We demonstrate here that the c-Jun N-terminal kinase inhibitor JIP-1, which binds JNK in the cytoplasm and interferes with its translocation and activity (Dickens et al., 1997) , partially abolishes HGF/ SF activation of ATF-2, indicating a role for this kinase in ATF-2 induction. Moreover transient transfection of JIP-1 into 37-32 melanoma cells partially abrogated HGF/SF-mediated cyclin D1 induction. Our results are in concordance with previous published data showing that cyclin D1 regulation by pp60 -v-src requires collaborative interactions between the MEK1/ERK, p38 and SAPK/JNK pathways in breast cancer cells .
In the present study we show that HGF/SF is a potent activator of ATF-2. p38 kinase and SAPK/JNK are implicated in ATF-2 activation, leading to the induction of cyclin D1. Moreover, we found that p38 kinase is partially responsible for HGF/SF-induced proliferation, but not motility. We conclude that the MEK1/ERK, SAPK/JNK and p38 pathways are necessary for the full induction of cyclin D1 and proliferation by HGF/SF in melanoma cells.
Materials and methods
Reagents
The antibodies used were from commercial sources: anti-cMet and anti-cyclin D1 (Santa Cruz), anti-phosphotyrosine (Upstate Biotech), anti-Actin (Boehringer Mannheim), antip38, anti-phospho-p38, anti-phospho-ATF-2, GST-ATF-2 (New England Biolabs) and anti-HA (Babco). Western blot detection was accomplished using horseradish peroxidasecoupled anti-mouse, anti-rabbit (Amersham Pharmacia Biotech) and anti-goat secondary antibodies (Santa Cruz). The MAPK inhibitors PD98059 and SB203508 were purchased from Cell Signaling Technologies. The PI3K inhibitors Wortmanin and LY294002 were from Upstate Biotechnology. The pCEFL-HA-p38, pCEFL-p38 dominant negative mutant and pCEFL-HA-JNK1 expression vectors were kind gifts from Dr S Gutkind (NIH). pBluscipt-Cyclin D1 was kindly provided by Dr CJ Sherr (St. Jude Children's Hospital), pJIP-1 by RJ Davis (University of Massachusetts Medical School) and the p-66-cyclin D1-Luc and pATF-2 dominant negative mutant by Dr R. Pestell (Albert Einstein Cancer Center).
Cell culture, transfection and stimulation
The mouse cell lines 37-32 and 37-3N were derived from melanomas arising in the HGF/SF transgenic mouse line MH37. Both cell lines were maintained in Dulbecco modi®ed Eagle medium (DMEM) (BRL, Gibco) supplemented with 10% fetal bovine serum (Harlan), 100 IU penicillin per ml, 100 mg streptomycin per ml, 2 mM L-glutamine (BRL, Gibco), 5 mg Insulin (Sigma) per ml, and 5 ng of epidermal growth factor (Upstate Biotechnology Inc.) per ml and incubated in 5% CO 2 at 378C. cDNAs were transfected using Lipofectamine Plus (BRL, Gibco) following the protocol recommended by the company. Treatments were done 24 ± 30 h after transfection. Cells were treated with 40 ng/ml of HGF/SF (R&D) and harvested at the time indicated in the ®gures.
Luciferase assays
Lysates were prepared from cells 24 h after HGF/SF treatment, and luciferase activity was detected using Luciferase Assay and Detection System from Pharmingen following the manufacturer's instructions. All experiments were done in triplicate and repeated at least three times.
Western blot and immunoprecipitation
Following HGF/SF treatment all cells were lysated with MPer (PIERCE) in the presence of a protease inhibitors cocktail (Boehringer-Mannheim Roche). Fifty mg of protein from lysates were separated by SDS ± PAGE using 4 ± 20% gradient gels (NOVEX). Proteins were transferred to nitrocellulose membranes (NOVEX) and probed against primary antibodies. Proteins were visualized with secondary antibodies coupled to horseradish peroxidase and developed using ECL-Plus reagent (Amersham Pharmacia Biotech). Immunoprecipitation was performed on lysates generated from 37-32 and 37-3N cells, prepared following a 5 min treatment with 40 ng/ml HGF/SF. Lysates were incubated with anti-c-Met antibody overnight at 48C. Following the addition of GammaBind TM G Sepharose TM (Amersham Pharmacia Biotech) and washing in M-PER buer, samples were fractionated by SDS ± PAGE using 4 ± 20% gradient gels (NOVEX). After transfer, blots were blocked and incubated with anti-c-Met antibody overnight. Bands were visualized by incubation with a secondary anti-rabbit antibody conjugated to horseradish peroxidase and ECL (Amersham). After stripping, membranes were blocked and incubated overnight against anti-phosphotyrosine monoclonal antibody (Upstate Biotech).
Northern blots
Thirty mg of total RNA was resolved on a denaturing 1% agarose formaldehyde agarose gel and transferred to a nitrocellulose membrane (Schleicher and Schuell; Chomczynski and Sacchi, 1987; Otshuka et al., 1998) . Membranes were prehybridized and hybridized using Expresshyb TM hybridization solution (Clontech) following the manufacturer's instructions, and subjected to autoradiography.
Proliferation and motility assays
For motility assays 5610 4 cells were seeded in a 24 multiwell plate trans-wells (Corning). Following treatment cells were washed with 16PBS and ®xed with 1% glutaraldehyde in PBS. Cells were then stained with an aqueous solution of 0.1% crystal violet. After destaining in water, non-migrating cells in the top of the trans-well were removed, and stained migrating cells in the bottom of the trans-well were destaining with PBS containing 0.2% Triton X-100. The O.D. was then measured at 590 nm (Gillies et al., 1986) . Proliferation analysis was performed using a colorimetric assay based on the cleavage in viable cells of the tetrazolium salt WST-1 (Roche Molecular Biochemicals) by mitochondrial dehydrogenases (Lai et al., 2000) . After cleavage WST-1 yields water soluble cleavage products which can be measured without an additional solubilization. Approximately 15 000 cells were seeded per well in a 96 multi-well plate, and after treatment WST-1 was added and incubated for 3 h. The O.D. was then measured at 440 nm. All the experiments were done in triplicate at least twice.
Kinase assays
Phosphorylation activity of epitope-tagged MAPK and JNK was determined as previously described (Coso et al., 1995) . The activity of the epitope-tagged kinases in 37-32 cells transiently transfected with expression vectors for HA-p38 and HA-JNK was assayed by following a similar protocol. Brie¯y, 24 h after transfection cells were incubated in serumfree medium for 2 h. After serum starvation they were stimulated for the time indicated with 40 ng/ml of HGF/SF. Cells were washed with cold phosphate-buered saline (PBS) and lysed at 48C in a buer containing 25 mM HEPES (pH 7.5), 0.3 M NaCl, 1.5 mM MgCl 2 0.2 mM EDTA, 0.5 mM dithiothreitol, 20 mM b-glycerophosphate, 1 mM vanadate, 1% Triton X-100, 1 mM phenyl-methylsulphonyl¯uoride (PMSF), 20 mg/ml of aprotinin and 20 mg/ml of leupeptin. Cleared lysates containing HA-tagged kinases were immunoprecipitated at 48C for 2 h with anti-HA.11 monoclonal antibody (Babco). Immunocomplexes were recovered with the aid of Gammabind TM G Sepharose TM (Amersham Pharmacia Biotech). Beads were washed three times with PBS containing 1% Nonidet P-40, 2 mM vanadate, once with 100 mM Tris (pH 7.5)-0.5 M LiCl and once with kinase reaction buer (12.5 mM MOPS [pH 7.5], 12.5 mM b-glycerophosphate, 7.5 mM MgCl 2 , 0.5 mm EGTA, 0.5 mM sodium¯uoride, 0.5 mM vanadate). Samples were then resuspended in 30 ml of kinase buer containing 1 mCi of [g 32 P] ATP per reaction and 20 mM of unlabeled ATP. After 20 min at 308C, the reactions were terminated by the addition of 10 ml of 56Laemmli buer. In vitro assays were performed with 2 mg of GST-ATF-2 fusion protein as a substrate.
